0001).

Logistic regression model demonstrated that FSSG (odds ratio [OR] 1.232, 95% confidence interval [CI]: 1.1221.352, p<0.0001) and 丫GT (OR: 1.011, 95%CI: 1.0031.019, p=0.00o) were independently associated with insomniacs. In treated-patients, AIS was significantly decreased with significant reductions of FSSG after the treatment with RPZ. Four patients of eleven insomnias (44%) were relieved after RPZ. Conclusions: In biopsy-proven NAFLD patients, insomnia was found in nearly thirty percent of cases, BTK inhibitor related to ۷GT and GERD symptoms, and can be relieved by RPZ. Disclosures: Kazuaki Chayama – Consulting: Abbvie; Grant/Research Support: Dainippon Sumitomo, Chugai, Mitsubishi Īanabe, DAIICHI SANKYO, Toray, BMS, MSD; Speaking and Teaching: Chugai, Mitsubishi Īanabe, DAIIcHi SANKYO, KYORIN, Nihon Medi-Physics, BMS, Dainippon Sumitomo, MSD, ASKA, Astellas, AstraZeneca, Eisai, Olympus, GlaxoSmithKline, ZERIA, Bayer, Minophagen, JANSSEN, JIMRO, TSUMURA, Otsuka, Taiho, Nippon Kayaku, Nippon Shinyaku, Takeda, AJINOMOTO, Meiji Seika, Toray The following people have nothing to disclose: Hiroyoshi Taketani, Yoshio Sumida, Saiyu Tanaka, Kazuyuki Kanemasa, Masato Yoneda, Kento Imajo, Atsushi Nakajima, Hideyuki Hyogo, Masafumi Ono, Toshiji Saibara, Hideki Fujii, Yuichiro Eguchi, Yoshito Itoh Background & Aims:

Patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) often have metabolic disorders including insulin resistance and type diabetes mellitus (T2DM). We clarified the predictive factors in glucose metabolism for progression of hepatic fibrosis in patients with NAFLD by the SAHA HDAC in vivo 75-g oral glucose tolerance test (75gOGTT) and a continuous glucose monitoring system MCE (CGMS). Methods: One hundred sixty-nine patients (68 female and 101 male patients) with biopsy-proven NAFLD with performance with 75gOGTT were enrolled and divided into four groups according to the stage of hepatic fibrosis

(F0-3). Results: The proportion of patients with T2DM significantly gradually increased, HbA1c and the homeostasis model assessment of insulin resistance were significantly elevated, and 1, 5-anhydroglucitol (1, 5-AG) was remarkably decreased with the progression of fibrosis. In the 75gOGTT, both plasma glucose and insulin secretion were remarkably increased with the progression of fibrosis. The only factor significantly associated with advanced fibrosis was 1, 5-AG (P = 0.008) as determined by multivariate logistic regression analysis. We next evaluated the changes in blood glucose during 24 hours by monitoring with the CGMS to confirm the relationship between glycemic variability and progression of fibrosis. Variability of median glucose, standard deviation of median glucose (P = 0.0022), maximum blood glucose (P = 0.0019), and AMin-max blood glucose (P = 0.0029) were remarkably higher in severe fibrosis than in mild fibrosis.